All In Biotech

Drug Trial Radar · NCT06740630

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

A Phase 3a, Observer-blind, Randomized, Controlled Study to Demonstrate Lot-to-lot Consistency and Evaluate the Immunogenicity and Safety of an Investigational Varicella Vaccine Compared With Varivax, Administered as a First Dose to Healthy Children 12 to 15 Months of Age

Last checked: Nov 19, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,840 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,840

Planned (sponsor's estimate)

Start

Jan 10, 2025

Primary completion

Dec 25, 2026

Study completion May 17, 2027

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Dec 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 12 months, up to 15 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the consistency of immune response to three different lots of GSK's investigational varicella vaccine (VNS Vaccine), and to compare the safety and immune response of VNS vaccine to an already approved varicella vaccine (VV) known as Varivax. The study will be conducted in healthy children aged 12 to 15 months, who have neither contracted varicella nor received a varicella vaccination.

Conditions

  • Chickenpox

Interventions

  • Investigational varicella vaccine_Lot 1Biological

    Investigational varicella vaccine of Lot 1 administered subcutaneously.

  • Investigational varicella vaccine_Lot 2Biological

    Investigational varicella vaccine of Lot 2 administered subcutaneously.

  • Investigational varicella vaccine_Lot 3Biological

    Investigational varicella vaccine of Lot 3 administered subcutaneously.

  • Marketed varicella vaccine_Lot 1Biological

    Marketed varicella vaccine of Lot 1 administered subcutaneously.

  • Marketed varicella vaccine_Lot 2Biological

    Marketed varicella vaccine of Lot 2 administered subcutaneously.

  • MMR vaccineBiological

    MMR vaccine co-administered subcutaneously or intramuscularly.

  • Hepatitis A vaccineBiological

    Hepatitis A vaccine co-administered intramuscularly.

  • PCV (pneumococcal conjugate vaccine) 13Biological

    The 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.

  • PCV 20Biological

    The 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.

  • VaxneuvanceBiological

    The Vaxneuvance (15-valent pneumococcal conjugate vaccine) co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with seroresponse to Varicella Zoster Virus (VZV) anti-glycoprotein E (gE) Immunoglobulin (IgG) for the 3 lots of VNS vaccine groupsTime frame: At Day 43
  2. Geometric Mean Concentration (GMC) of anti-VZV gE IgG for the 3 lots of VNS vaccine groupsTime frame: At Day 43
  3. Percentage of participants with seroresponse to anti-VZV gE IgG for the 3 pooled lots of VNS vaccine groups compared with the 2 pooled lots of VV groupsTime frame: At Day 43
  4. GMCs of anti-VZV gE IgG for the 3 pooled lots of VNS vaccine groups compared with the 2 pooled lots of VV groupsTime frame: At Day 43

Locations

97 sites in 11 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Mobile, Alabama · Recruiting

  • GSK Investigational Site

    Hot Springs, Arkansas · Recruiting

  • GSK Investigational Site

    Sherwood, Arkansas · Recruiting

  • GSK Investigational Site

    Canoga Park, California · Recruiting

  • GSK Investigational Site

    Covina, California · Recruiting

  • GSK Investigational Site

    Fullerton, California · Withdrawn

  • GSK Investigational Site

    Long Beach, California · Withdrawn

  • GSK Investigational Site

    Los Angeles, California · Recruiting

  • GSK Investigational Site

    Paramount, California · Withdrawn

  • GSK Investigational Site

    Sacramento, California · Recruiting

  • GSK Investigational Site

    Ventura, California · Recruiting

  • GSK Investigational Site

    Walnut Creek, California · Recruiting

  • GSK Investigational Site

    Winnetka, California · Recruiting

  • GSK Investigational Site

    Miami, Florida · Withdrawn

  • GSK Investigational Site

    Miami, Florida · Recruiting

  • GSK Investigational Site

    Miami Lakes, Florida · Recruiting

  • GSK Investigational Site

    Spring Hill, Florida · Recruiting

  • GSK Investigational Site

    Tampa, Florida · Recruiting

  • GSK Investigational Site

    Covington, Georgia · Recruiting

  • GSK Investigational Site

    Ammon, Idaho · Recruiting

  • GSK Investigational Site

    Moline, Illinois · Recruiting

  • GSK Investigational Site

    South Bend, Indiana · Recruiting

  • GSK Investigational Site

    Topeka, Kansas · Recruiting

  • GSK Investigational Site

    Bardstown, Kentucky · Recruiting

  • GSK Investigational Site

    Louisville, Kentucky · Recruiting

  • GSK Investigational Site

    Haughton, Louisiana · Recruiting

  • GSK Investigational Site

    Fall River, Massachusetts · Recruiting

  • GSK Investigational Site

    Bingham Farms, Michigan · Recruiting

  • GSK Investigational Site

    Jefferson City, Missouri · Recruiting

  • GSK Investigational Site

    Lincoln, Nebraska · Recruiting

  • GSK Investigational Site

    Lincoln, Nebraska · Withdrawn

  • GSK Investigational Site

    Lincoln, Nebraska · Recruiting

  • GSK Investigational Site

    The Bronx, New York · Recruiting

  • GSK Investigational Site

    Charlotte, North Carolina · Recruiting

  • GSK Investigational Site

    Monroe, North Carolina · Withdrawn

  • GSK Investigational Site

    Cleveland, Ohio · Recruiting

  • GSK Investigational Site

    Dayton, Ohio · Recruiting

  • GSK Investigational Site

    Chickasha, Oklahoma · Recruiting

  • GSK Investigational Site

    Tulsa, Oklahoma · Recruiting

  • GSK Investigational Site

    Gresham, Oregon · Recruiting

Showing 40 of 97 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.